- Home
- ALMS vs NYXH Comparison
ALMS vs NYXH Comparison
Compare ALMS & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALMS
- NYXH
- Stock Information
- Founded
- ALMS 2021
- NYXH 2009
- Country
- ALMS United States
- NYXH Belgium
- Employees
- ALMS N/A
- NYXH N/A
- Industry
- ALMS
- NYXH Medical/Dental Instruments
- Sector
- ALMS
- NYXH Health Care
- Exchange
- ALMS NYSE
- NYXH Nasdaq
- Market Cap
- ALMS 402.6M
- NYXH 394.1M
- IPO Year
- ALMS 2024
- NYXH 2021
- Fundamental
- Price
- ALMS $5.00
- NYXH $6.04
- Analyst Decision
- ALMS Strong Buy
- NYXH Strong Buy
- Analyst Count
- ALMS 7
- NYXH 4
- Target Price
- ALMS $28.17
- NYXH $14.75
- AVG Volume (30 Days)
- ALMS 1.6M
- NYXH 283.0K
- Earning Date
- ALMS 05-15-2025
- NYXH 05-13-2025
- Dividend Yield
- ALMS N/A
- NYXH N/A
- EPS Growth
- ALMS N/A
- NYXH N/A
- EPS
- ALMS N/A
- NYXH N/A
- Revenue
- ALMS N/A
- NYXH $4,680,609.00
- Revenue This Year
- ALMS N/A
- NYXH $504.18
- Revenue Next Year
- ALMS N/A
- NYXH $149.52
- P/E Ratio
- ALMS N/A
- NYXH N/A
- Revenue Growth
- ALMS N/A
- NYXH 3.98
- 52 Week Low
- ALMS $3.18
- NYXH $5.55
- 52 Week High
- ALMS $13.53
- NYXH $12.21
- Technical
- Relative Strength Index (RSI)
- ALMS N/A
- NYXH 30.06
- Support Level
- ALMS N/A
- NYXH $5.62
- Resistance Level
- ALMS N/A
- NYXH $6.37
- Average True Range (ATR)
- ALMS 0.00
- NYXH 0.56
- MACD
- ALMS 0.00
- NYXH -0.01
- Stochastic Oscillator
- ALMS 0.00
- NYXH 24.74
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.